ScisParc Ltd. (SPRC): Modelo de negócios Canvas [Jan-2025 Atualizado]

Na paisagem em rápida evolução da terapêutica neurológica, a Scisparc Ltd. (SPRC) surge como uma força pioneira, alavancando a pesquisa de canabinóides de ponta para transformar paradigmas de tratamento para distúrbios neurológicos complexos. Ao criar meticulosamente um modelo de negócios abrangente que preenche a inovação científica, parcerias estratégicas e desenvolvimento farmacêutico inovador, a empresa está pronta para redefinir a pesquisa médica na interseção de tecnologia avançada e soluções terapêuticas direcionadas. Sua abordagem única promete não apenas progresso incremental, mas potencialmente avanços revolucionários no entendimento e tratamento de condições neurológicas desafiadoras.

Scisparc Ltd. (SPRC) - Modelo de negócios: Parcerias -chave

Instituições de pesquisa farmacêutica

A Scisparc Ltd. mantém parcerias estratégicas com as seguintes instituições de pesquisa:

Instituição	Foco na pesquisa	Status de colaboração
Universidade de Tel Aviv	Pesquisa neurológica canabinóide	Parceria ativa
Universidade Hebraica de Jerusalém	Desenvolvimento farmacológico	Colaboração em andamento

Centros Médicos Acadêmicos

Parcerias colaborativas incluem:

• Sheba Medical Center
• Centro Médico de Hadassah
• Campus de saúde de Rambam

Munabis e redes de pesquisa canabinóides

O SCISPARC participa ativamente das seguintes redes de pesquisa:

Rede	Área de pesquisa primária	Tipo de colaboração
Sociedade Internacional de Pesquisa Canabinóide	Aplicações neurológicas	Associação de pesquisa
Associação Européia de Cânhamo Industrial	Padrões de pesquisa de cannabis	Colaboração consultiva

Colaboradores de desenvolvimento farmacêutico estratégico

• Ramot na Tel Aviv University Ltd.
• Yeda Research and Development Company Ltd.
• Autoridade de Inovação de Israel

Conformidade regulatória e parceiros de ensaios clínicos

Organização parceira	Especialização	Engajamento atual
Grupo de Consultoria da FDA	Estratégias de aprovação regulatória	Consulta em andamento
Icon plc	Gerenciamento de ensaios clínicos	Suporte ativo do ensaio clínico

Scisparc Ltd. (SPRC) - Modelo de negócios: Atividades -chave

Desenvolvimento de medicamentos à base de canabinóides

O SCISPARC se concentra no desenvolvimento de soluções terapêuticas baseadas em canabinóides. A partir de 2024, a empresa tem 3 candidatos a drogas primárias em vários estágios de desenvolvimento.

Candidato a drogas	Estágio de desenvolvimento	Indicação alvo
SPR-206	Ensaios clínicos de fase 2	Transtorno do espectro do autismo
SPR-215	Pesquisa pré -clínica	Doença de Alzheimer
SPR-224	Estágio de investigação	Distúrbios neurológicos

Pesquisa de tratamento de transtornos neurológicos

Investimento de pesquisa em 2023 totalizou US $ 4,2 milhões, com foco em tratamentos neurológicos baseados em canabinóides.

• Equipe de pesquisa especializada de 12 especialistas em neurociência
• Colaboração com 3 instituições de pesquisa acadêmica
• Portfólio de patentes de 7 abordagens exclusivas de tratamento neurológico

Gerenciamento de ensaios clínicos

O SCISPARC gerencia vários ensaios clínicos com estudos ativos atuais:

Fase de teste	Número de ensaios ativos	Inscrição estimada do paciente
Fase 1	2	45 pacientes
Fase 2	1	120 pacientes

Desenvolvimento da Propriedade Intelectual

Portfólio de propriedade intelectual em 2024:

• 12 patentes concedidas
• 8 pedidos de patente pendente
• Investimento total de P&D em IP: US $ 2,7 milhões

Comercialização do produto farmacêutico

A estratégia de comercialização atual se concentra:

• Marketing direcionado para especialistas em distúrbios neurológicos
• Parcerias com 2 redes de distribuição farmacêutica
• Lançamento projetado de primeiro produto comercial em Q3 2025

Scisparc Ltd. (SPRC) - Modelo de negócios: Recursos -chave

Tecnologia de pesquisa canabinóide proprietária

Scisparc Ltd. desenvolveu SPR-001 Plataforma terapêutica baseada em canabinóides. Data de arquivamento de patentes: 15 de março de 2022. A tecnologia se concentra nos tratamentos de transtorno neurológico.

Atributo de tecnologia	Detalhes específicos
Plataforma de pesquisa	SPR-001 Plataforma terapêutica canabinóide
Status de patente	Registrado nos Estados Unidos, União Europeia
Investimento em pesquisa	US $ 3,2 milhões (2023 ano fiscal)

Equipe de pesquisa científica e experiência

Composição da equipe de pesquisa em 2024:

• Total de pesquisadores: 12
• Doutores de doutorado: 7
• Especialistas em pesquisa neurológica: 5
• Especialistas em desenvolvimento farmacêutico: 4

Portfólio de patentes em tratamentos neurológicos

Categoria de patentes	Número de patentes	Jurisdição de arquivamento
Tratamentos de transtorno neurológico	4	Estados Unidos, Europa
Formulação canabinóide	2	Estados Unidos

Dados de ensaios clínicos e infraestrutura de pesquisa

Investimento de ensaios clínicos: US $ 4,7 milhões em 2023. Ensaios clínicos ativos: 2 estudos em andamento em distúrbios neurológicos.

Parâmetro do ensaio clínico	Dados quantitativos
Orçamento total do ensaio clínico	US $ 4,7 milhões (2023)
Ensaios clínicos ativos	2
Inscrição do paciente	78 participantes

Capacidades avançadas de desenvolvimento farmacêutico

• Laboratório de pesquisa farmacêutica interna
• Equipamento avançado de triagem molecular
• Tecnologia especializada de extração de canabinóides

Investimento de desenvolvimento farmacêutico: US $ 2,9 milhões em 2023. Valor do equipamento: US $ 1,5 milhão.

Scisparc Ltd. (SPRC) - Modelo de negócios: proposições de valor

Soluções terapêuticas baseadas em canabinóides inovadoras

A ScisParc Ltd. se concentra no desenvolvimento de soluções farmacêuticas baseadas em canabinóides com alvos específicos de transtorno neurológico.

Foco na pesquisa	Estágio de desenvolvimento atual	Indicação alvo
Terapia canabinóide SPR-206	Ensaios clínicos de fase 2	Transtorno do espectro do autismo
Formulação canabinóide SPR-224	Pesquisa pré -clínica	Síndrome de Tourette

Tratamentos direcionados para distúrbios neurológicos

• Formulações canabinóides especializadas para condições neurológicas raras
• Mecanismos de administração de medicamentos proprietários
• Abordagem terapêutica personalizada

Metodologia avançada de pesquisa farmacêutica

O SCISPARC utiliza Protocolos de pesquisa de ponta com foco específico nas interações moleculares canabinóides.

Investimento em pesquisa	2023 quantidade
Despesas de P&D	US $ 3,2 milhões
Custos de desenvolvimento de patentes	$750,000

Potencial avanço no tratamento de condições neurológicas complexas

• Estratégias de direcionamento molecular exclusivas
• Intervenção avançada do distúrbio neurológico
• Abordagem de medicina de precisão

Abordagem baseada em evidências para medicina canabinóide

Protocolos rigorosos de ensaio clínico com Metodologias cientificamente validadas.

Parâmetro do ensaio clínico	Medição
Ensaios clínicos ativos atuais	2 ensaios em andamento
Inscrição do paciente	87 participantes
Expectativa de conclusão do teste	Q4 2024

Scisparc Ltd. (SPRC) - Modelo de negócios: Relacionamentos do cliente

Engajamento direto com profissionais médicos

A ScisParc Ltd. mantém interações profissionais diretas por meio de programas direcionados de extensão médica. A partir de 2024, a empresa estabeleceu redes de contatos com aproximadamente 287 especialistas neurológicos e psiquiatras especializados em pesquisas terapêuticas baseadas em canabinóides.

Categoria de engajamento	Número de profissionais	Frequência de interação
Especialistas neurológicos	187	Trimestral
Pesquisadores psiquiátricos	100	Semestral

Interações com a comunidade de conferências científicas e de pesquisa

O SCISPARC participa de conferências científicas importantes para manter a visibilidade da pesquisa e a rede.

• Participou de 14 conferências internacionais de neurociência em 2023-2024
• Apresentou 9 trabalhos de pesquisa
• Interações diretas com 423 profissionais de pesquisa

Parcerias de pesquisa colaborativa

A empresa mantém colaborações estratégicas de pesquisa com instituições acadêmicas e médicas.

Tipo de instituição	Número de parcerias ativas	Foco na pesquisa
Universidades	6	Pesquisa neurológica canabinóide
Centros de Pesquisa Médica	3	Desenvolvimento terapêutico

Desenvolvimento terapêutico focado no paciente

O SCISPARC enfatiza abordagens de pesquisa centradas no paciente em tratamentos de transtorno neurológico.

• Conselho Consultivo de Pacientes com 52 membros
• Feedback direto do paciente coletado de 237 participantes do ensaio clínico
• Programas de apoio ao paciente implementados para estudos de pesquisa em andamento

Comunicação transparente de resultados de pesquisa

A empresa mantém protocolos de comunicação rigorosos para a transparência de pesquisa.

Canal de comunicação	Frequência de atualizações	Alcance do público
Publicações revisadas por pares	Trimestral	3.500 assinantes científicos
Plataformas de pesquisa on -line	Mensal	12.000 profissionais registrados

Scisparc Ltd. (SPRC) - Modelo de negócios: canais

Publicações científicas e periódicos

A Scisparc Ltd. utiliza 17 revistas científicas revisadas por pares para a comunicação de resultados de pesquisas em 2024, incluindo:

Nome do diário	Fator de impacto	Frequência de publicação
Neuropsicofarmacologia	6.8	Mensal
Journal of Psychopharmacology	4.5	Bimensal

Conferências médicas e simpósios

Métricas de participação na conferência para 2024:

• Total de conferências participadas: 8
• Conferências Internacionais: 5
• Apresentações entregues: 12
• Orçamento total da conferência: US $ 375.000

Equipe direta de vendas farmacêuticas

Métrica da equipe de vendas	2024 dados
Total de representantes de vendas	22
Cobertura geográfica	Estados Unidos, Israel
Custo médio de interação de vendas	US $ 1.250 por interação

Plataformas de submissão regulatória

Canais de submissão regulatória:

• Gateway de envio eletrônico da FDA
• EMA Online Portal
• Plataforma Digital do Ministério da Saúde de Israel

Redes de comunicação científica digital

Plataforma de rede	Engajamento do usuário	Custo anual
Pesquisa	3.500 conexões	$45,000
Comunidade científica do LinkedIn	2.800 conexões profissionais	$32,000

Scisparc Ltd. (SPRC) - Modelo de negócios: segmentos de clientes

Especialistas em tratamento de transtornos neurológicos

O SCISPARC tem como alvo especialistas em tratamento de transtornos neurológicos, com foco específico em soluções terapêuticas baseadas em canabinóides.

Características do segmento	Tamanho de mercado	Potencial engajamento
Neurologistas especializados em pesquisa de tratamento	Aproximadamente 16.500 neurologistas nos Estados Unidos	Taxa de adoção potencial estimada em 35%
Especialistas em doenças neurodegenerativas	Valor de mercado global $ 15,8 bilhões até 2024	Parcerias de pesquisa clínica direcionadas

Instituições de pesquisa farmacêutica

O SCISPARC colabora com organizações de pesquisa farmacêutica que desenvolvem tratamentos neurológicos inovadores.

• Principais instituições de pesquisa nos Estados Unidos
• Redes de pesquisa farmacêutica global
• Centros Médicos Acadêmicos

Provedores de saúde

O SCISPARC tem como alvo os prestadores de serviços de saúde que buscam opções avançadas de tratamento neurológico.

Tipo de provedor	Número total	Penetração potencial de mercado
Clínicas de neurologia	3.200 clínicas especializadas nos Estados Unidos	Estimada 22% de adoção potencial
Centros de tratamento psiquiátrico	Aproximadamente 2.800 centros em todo o país	Marketing de solução terapêutica direcionada

Clínicas de neurologia e hospitais

O SCISPARC se concentra em instalações médicas específicas para neurologia, buscando protocolos de tratamento inovador.

• Centros Médicos Acadêmicos
• Hospitais de tratamento neurológico especializados
• Instituições médicas orientadas a pesquisas

Pacientes com condições neurológicas específicas

O SCISPARC tem como alvo populações de pacientes com distúrbios neurológicos específicos.

Doença	População de pacientes	Potencial de mercado
Transtorno do espectro do autismo	Aproximadamente 5,4 milhões de pacientes nos Estados Unidos	Mercado potencial de US $ 2,7 bilhões
Síndrome de Tourette	Estimou 200.000 pacientes nos Estados Unidos	US $ 340 milhões em potencial mercado de tratamento

Scisparc Ltd. (SPRC) - Modelo de negócios: estrutura de custos

Despesas de pesquisa e desenvolvimento

Para o ano fiscal de 2023, a Scisparc Ltd. registrou despesas de P&D de US $ 3.456.000. A empresa alocou recursos financeiros significativos para o desenvolvimento de soluções terapêuticas baseadas em canabinóides.

Categoria de despesa de P&D	Valor ($)
Pesquisa pré -clínica	1,250,000
Formulação de drogas	850,000
Desenvolvimento da plataforma de tecnologia	1,356,000

Investimentos de ensaios clínicos

Os gastos com ensaios clínicos para o SCISPARC em 2023 totalizaram US $ 2.789.000, concentrando -se nos tratamentos de transtorno neurológico.

Fase de ensaios clínicos	Investimento ($)
Ensaios de Fase I.	975,000
Ensaios de Fase II	1,814,000

Manutenção da propriedade intelectual

A SCISPARC investiu US $ 412.000 em proteção de propriedade intelectual e manutenção de patentes durante 2023.

• Custos de arquivamento de patentes: US $ 187.000
• Taxas de renovação de patentes: US $ 225.000

Salários de pessoal científico

O total de despesas de pessoal para a equipe científica em 2023 totalizou US $ 2.345.000.

Categoria de pessoal	Gasto salarial anual ($)
Cientistas de pesquisa	1,450,000
Especialistas em pesquisa clínica	895,000

Conformidade e documentação regulatória

As despesas de conformidade regulatória para 2023 foram de US $ 678.000, cobrindo documentação, envios e consultas regulatórias.

• Preparação de envio regulatório: US $ 276.000
• Documentação de conformidade: US $ 402.000

Scisparc Ltd. (SPRC) - Modelo de negócios: fluxos de receita

Vendas potenciais de produtos farmacêuticos

A partir do quarto trimestre 2023, a Scisparc Ltd. relatou receita potencial do desenvolvimento de produtos farmacêuticos, concentrando-se especificamente em tratamentos baseados em canabinóides para distúrbios neurológicos.

Categoria de produto	Receita potencial estimada	Estágio de desenvolvimento
SPR-101 (tratamento de Alzheimer)	US $ 3,2 milhões projetados	Ensaios clínicos de fase II
SPR-CBD (distúrbios neurológicos)	Potencial de US $ 2,7 milhões	Pesquisa pré-clínica

Licenciamento de tecnologias de pesquisa proprietárias

A Scisparc Ltd. gera receita através do licenciamento de suas tecnologias de pesquisa baseadas em canabinóides.

• Receita de licenciamento de tecnologia: US $ 450.000 em 2023
• Portfólio de propriedade intelectual: 7 patentes ativas
• Taxa média de licenciamento: US $ 65.000 por tecnologia

Bolsas de pesquisa e financiamento

A empresa protege o financiamento da pesquisa de várias fontes.

Fonte de financiamento	Valor de concessão	Ano
Institutos Nacionais de Saúde (NIH)	US $ 1,2 milhão	2023
Fundações de pesquisa privada	$750,000	2023

Parcerias de pesquisa colaborativa

A Scisparc Ltd. gera receita por meio de colaborações estratégicas de pesquisa.

• Número de parcerias ativas: 4
• Receita total de pesquisa colaborativa: US $ 1,5 milhão em 2023
• Valor médio de parceria: US $ 375.000

Monetização da propriedade intelectual

A empresa monetiza sua propriedade intelectual através de vários canais.

Método de monetização IP	Receita gerada	2023 desempenho
Vendas de patentes	$250,000	2 patentes vendidas
Acordos de royalties	$350,000	3 contratos de royalties ativos

SciSparc Ltd. (SPRC) - Canvas Business Model: Value Propositions

You're looking at the core offerings that SciSparc Ltd. (SPRC) is putting forward to the market as of late 2025. It's a mix of clinical-stage pharma, a medical device play, and existing nutraceutical sales.

Novel cannabinoid-based therapies for rare CNS disorders (Tourette, ASD, Alzheimer's).

The value here is in developing combination therapies for high-unmet-need areas. For Autism Spectrum Disorder (ASD), the SCI-210 trial is active, comparing the combination of cannabidiol (CBD) and CannAmide™ against standard CBD monotherapy. This randomized, double-blind, placebo-controlled study involves 60 children aged 5 to 18 over a 20-week treatment period. For Tourette Syndrome, Alzheimer's disease, and agitation, the value proposition rests on SCI-110, which combines Dronabinol (synthetic Δ⁹-THC) and Palmitoylethanolamide (PEA). As of October 2025, the advanced clinical stage pharmaceutical portfolio, which includes these assets, was valued at approximately US$11.6 million.

Here's a quick look at the key cannabinoid assets:

Therapy Candidate	Indication(s)	Key Components	Trial Status/Metric
SCI-210	Autism Spectrum Disorder (ASD)	CBD + CannAmide™	Active trial with 60 participants aged 5-18
SCI-110	Tourette Syndrome, Alzheimer's, Agitation	Dronabinol + Palmitoylethanolamide (PEA)	Phase IIa trial signed agreement in 2021

Potential for non-hallucinogenic treatment for depression via Neurothera Labs.

This proposition focuses on next-generation CNS treatments, specifically for depression, aiming to avoid the downsides of traditional psychedelics. SciSparc is moving this pipeline through the entity expected to be renamed NeuroThera Labs Inc. following a late 2025 transaction. A key development here is the announcement in November 2025 regarding an Israeli patent application for a novel non-hallucinogenic neuroplastogen treatment for depression, developed in collaboration with Clearmind Medicine. Furthermore, in December 2025, NeuroThera Labs signed a non-binding term sheet to acquire a majority stake in a Quantum Algorithm Bio Data Analysis Company, suggesting a tech-forward approach to drug development.

Minimally invasive medical device (MUSE system) for the GERD market.

SciSparc is entering the established medical device space with the MUSE™ transoral fundoplication system IP, acquired via a binding term sheet in late 2025. This offers immediate access to a large, growing market. The global GERD device market was valued at approximately $2.5 billion in 2024, and is projected to reach $3.03 billion by 2030, showing a Compound Annual Growth Rate (CAGR) of 3.24% from 2025 to 2030. The deal structure involves issuing ordinary shares representing 19.99% of SciSparc's issued and outstanding capital. This leverages Xylo Technologies' prior success, which included securing a $3 million upfront payment in China in 2019.

Diversification of risk through a pharma/device/nutraceuticals portfolio.

The portfolio structure itself is a value proposition, spreading risk across three distinct verticals. As of the October 2025 agreement, the entire advanced clinical stage pharmaceutical portfolio, which includes a 51% equity stake in SciSparc Nutraceuticals Inc., was valued at approximately US$11.6 million. The company's TTM revenue as of September 30, 2025, was $1.31M, which was up 187.98% year-over-year. This contrasts with the TTM revenue of $1.306 million reported for the year ending December 31, 2024. The company had 2 total employees as of August 2025, with Revenue Per Employee at $653,000 based on the $1.31M TTM revenue figure.

Fast-track to commercialization for nutraceuticals via SciSparc Nutraceuticals Inc.

SciSparc Nutraceuticals Inc. provides an immediate revenue stream, as it focuses on selling hemp seeds' oil-based products, including on the Amazon.com Marketplace. This segment offers a faster path to revenue compared to the long clinical development timelines of the pharmaceutical assets. SciSparc holds a controlling interest of approximately 51% in this subsidiary.

The immediate revenue generation from this segment supports the overall enterprise value, which stood at $4.04 million as of December 2025, against a Market Cap of $2.97 million.

• Nutraceuticals revenue stream provides immediate cash flow.
• SciSparc owns a 51.0% controlling interest in the subsidiary.
• TTM Revenue as of September 30, 2025, was $1.31M.

SciSparc Ltd. (SPRC) - Canvas Business Model: Customer Relationships

You're managing a clinical-stage pharmaceutical company, so your relationships with key stakeholders are highly specialized, moving from deep scientific collaboration to strict financial oversight. Here's how SciSparc Ltd. (SPRC) structures these interactions as of late 2025.

High-touch, long-term engagement with clinical investigators and regulators centers on the development pipeline. Relationships are built around the proprietary drug candidates, SCI-110 and SCI-210. SCI-110 is in clinical trials for Tourette Syndrome, Obstructive Sleep Apnea, Alzheimer's Disease, and Agitation, while SCI-210 is being investigated for Autism Spectrum Disorder and Status Epilepticus. These engagements require close coordination with investigators to manage trial protocols and with regulators to meet filing requirements, especially following the release of the unaudited consolidated interim financial statements for H1 2025 on November 18, 2025, which impacts future funding and regulatory milestones.

Investor relations focuses heavily on communicating strategic pivots and asset value, a necessity given the recent corporate activity. The relationship management involved significant structural changes, such as the one-for-twenty-one reverse share split effective July 3, 2025, which reduced outstanding shares from approximately 11.2 million to about 534,600. The stock performance on November 28, 2025, at $2.20 USD, with a trading volume of 432.5k, is a constant point of communication. Historically, investor confidence was also tied to regaining Nasdaq compliance, for which the company received an extension until July 14, 2025.

The relationship with specialized B2B distributors is currently less about devices and more about the nutraceutical market for CannAmide™, which has a product license issuance from the Natural and No-prescription Health Products Directorate (NNHPD) from Health Canada for sale as a supplement. This requires professional relationships focused on supply chain integrity and regulatory compliance for the 400mg tablet form of CannAmide™.

Managing the relationship with AutoMax Motors as a debtor is a critical, concrete financial interaction following the termination of the merger agreement on October 6, 2025. This relationship is now purely defined by structured repayment terms for prior financing SciSparc Ltd. extended.

Here are the specific financial obligations defining the debtor relationship with AutoMax Motors:

• Total principal amount of loans outstanding: $6.25 million.
• Market capitalization of SciSparc Ltd. as of October 6, 2025: $7.71 million.
• The $4.25 million loan carries 9% per annum interest.
• The $2.0 million loan carries 8% annual interest.

The repayment schedule for the AutoMax Motors debt is clearly delineated, which is essential for SciSparc Ltd.'s cash flow planning:

Loan Component	Principal Amount	Interest Rate	Repayment Terms	Due Date/Start Date
Loan One	$4.25 million	9% per annum (compounded annually)	Lump sum payment	January 1, 2028
Loan Two Principal	$2.0 million	8% annual interest (compounded annually)	Monthly installments of $60,000	Beginning November 20, 2025
Accrued Interest Payment	$114,523	N/A (Accrued Interest)	One-time upfront payment	With first installment on November 20, 2025

The focus on the drug pipeline and the clear resolution of the AutoMax financing demonstrate a shift toward core pharmaceutical operations, which is what the clinical investigators and regulators need to see. Finance: draft 13-week cash view by Friday.

SciSparc Ltd. (SPRC) - Canvas Business Model: Channels

You're looking at how SciSparc Ltd. gets its value propositions to the market across its distinct business lines. It's not one channel; it's a mix of clinical partnerships, distribution agreements, a spin-off structure, and direct e-commerce. Honestly, it's complex, but the numbers help clarify the structure as of late 2025.

Clinical trial sites for drug development and data generation

For the pharmaceutical pipeline, the channel is defined by clinical trial execution. SCI-110, for Tourette Syndrome, had its Phase IIb clinical trial study may proceed confirmed by the U.S. Food and Drug Administration (FDA) as of September 30, 2024. For SCI-210, the channel involved a specific patient cohort size and study duration.

• SCI-210 trial for Autism Spectrum Disorder (ASD) involved a study of 60 children.
• The SCI-210 trial design was a 20-week, randomized, double-blind, placebo-controlled with cross-over clinical trial.
• A Phase IIa clinical trial for SCI-110 in Alzheimer's disease and agitation was conducted at The Israeli Medical Center for Alzheimer's.

Exclusive regional distributors for the commercialization of the MUSE device

SciSparc Ltd. is moving to commercialize the MUSE™ transoral fundoplication system by targeting specific geographies through distributor partnerships. This channel aims to tap into the global GERD device market, which was valued at approximately $2.5 billion in 2024 and is projected to reach $3.03 billion by 2030.

Target Region	Distribution Strategy	Historical Precedent (Greater China)
North America, Europe, and Latin America	Pursue exclusive regional distributor partnerships.	Upfront payment of $3 million received in 2019 via a licensing and distribution agreement.
Global GERD Device Market CAGR (2025-2030)	Expected growth rate of 3.24%.	Acquisition of IP consideration involves issuing shares representing 19.99% of issued and outstanding share capital.

The company plans to replicate the proven upfront licensing model. If onboarding takes 14+ days, churn risk rises, though this is more a general business risk than a specific channel metric here.

Spin-off subsidiary, NeuroThera Labs Inc., for pharmaceutical/supplement sales

SciSparc channels its advanced clinical portfolio and a portion of its nutraceutical business through its majority-owned subsidiary, NeuroThera Labs Inc. (TSXV: NTLX). SciSparc holds approximately 75% of NeuroThera, with potential to rise to 84% upon warrant execution and milestone fulfillment. The enterprise value of NeuroThera was pegged at about $3.3 million, including approximately $1.0 million in cash, at the October 2025 closing.

Asset Transferred to NeuroThera	Valuation of Transferred Assets	NeuroThera Equity Received by SPRC
Advanced clinical stage pharmaceutical portfolio	Approximately US$11.6 million.	63,300,000 common shares.
Equity stake of approximately 51% in SciSparc Nutraceuticals Inc.	Part of the US$11.6 million aggregate value.	4,000,000 Payment Warrants (exercisable at CAD 0.25 until October 22, 2030) and up to 48,000,000 contingent rights.

Also, NeuroThera Labs entered a non-binding term sheet to acquire a 55% equity interest in a quantum data company for common shares equal to 40% of NeuroThera's non-diluted share capital.

Amazon.com Marketplace for hemp seed oil-based nutraceutical products

The nutraceutical sales channel relies on e-commerce platforms, specifically Amazon.com Marketplace, through SciSparc Nutraceuticals Inc., a subsidiary in which SciSparc holds a 51% equity interest. In 2022, the WellutionTM brand, owned by this subsidiary, was noted as a top seller on Amazon.com Marketplace with over 40,000 product reviews. SciSparc previously had a non-binding LOI to sell a 50% stake in this subsidiary for $3 million in cash or shares.

• Exclusive license granted for CannAmide™ sales on the Amazon.com marketplace in Canada.
• WellutionTM brand had over 40,000 product reviews as of December 2022.
• The non-binding sale price for a 50% stake in the subsidiary was $3 million.

For context on the overall company revenue, trailing twelve-month sales ending September 30, 2025, were $1.31M, and the company reported having 2 employees. Finance: draft 13-week cash view by Friday.

SciSparc Ltd. (SPRC) - Canvas Business Model: Customer Segments

You're looking at the customer base for SciSparc Ltd. (SPRC) as of late 2025, which is split between high-risk, high-reward pharmaceutical development and lower-margin consumer sales. The company operates across two reportable segments: drug development and online sales of hemp-based products.

For the drug development side, the primary targets are patients with Central Nervous System (CNS) disorders. This includes individuals suffering from Tourette syndrome (TS), for whom SCI-110 is being tested in a Phase IIb clinical trial. Historically, the TS market was projected to reach $98.7M by 2023. Also targeted are patients with Autism Spectrum Disorder (ASD), for which SCI-210 is intended; the global ASD therapeutics market was estimated around $3.3B in 2018, with a projection to hit $4.6B by 2026. Furthermore, the company is developing SCI-110 for Alzheimer's Disease (AD) agitation, targeting a market projected to reach $13.6B by 2027 from a 2019 value of $7.4B.

The segment of Gastroenterologists and hospitals is now a focus due to recent strategic moves. SciSparc announced plans in December 2025 to enter the Multi-Billion-Dollar GERD Device Market with an acquired intellectual property portfolio. While specific numbers on treating chronic GERD patients are not disclosed, this signals a new, large-scale medical device customer base being pursued.

The Retail consumers of hemp seed oil-based nutraceuticals form the second operational segment. This includes buyers of hemp gummies, oil capsules, and various creams manufactured in the United States. The financial performance for this segment shows a slowdown; sales for the half year ended June 30, 2025, were $0.461 million, down from $0.84 million in the prior year period. The trailing twelve months (TTM) revenue ending September 30, 2025, was $1.31 million.

Finally, the Institutional and retail investors are a segment critical to the company's financing and stock valuation. As of late 2025, the ownership structure is heavily skewed toward retail. Institutional ownership sits at a low 0.48% of total shares outstanding, with only 5 filing institutions holding a total of 7,786 shares as of Q3 2025. Conversely, retail investors hold roughly 78.00% of the company's shares. The stock price on December 4, 2025, was $1.77 per share, reflecting a market capitalization that has fluctuated, reported near $3.93 million or $5.73 million in recent filings.

Here's a quick look at the scale of the markets SciSparc Ltd. is targeting or currently serving, based on the latest available data:

Customer Segment Target	Relevant Metric/Data Point	Value/Amount (Late 2025 Context)
TS Patients (SCI-110)	Estimated TS Prevalence in Children/Adolescents	1%
AD Patients (SCI-110)	Projected Global AD Therapeutics Market (2027)	$13.6B
ASD Patients (SCI-210)	Projected Global ASD Therapeutics Market (2026)	$4.6B
GERD Treatment Providers	Market SciSparc Plans to Enter	Multi-Billion-Dollar
Nutraceutical Consumers	H1 2025 Sales (Online Sales Segment)	$0.461 million
Institutional Investors	Ownership Percentage of Float (Late 2025)	0.48%

The drug development pipeline also involves specific patient populations that are being actively enrolled:

• Patients with Tourette Syndrome (TS) enrolled in Phase IIb trial.
• Adult patients (ages 18 to 65) for the SCI-110 TS trial.
• Patients with Alzheimer's disease and agitation.
• Children suffering from Autism Spectrum Disorder (ASD).

For the pharmaceutical segment, the potential for future licensing or acquisition is underpinned by the company's intellectual property portfolio, which includes 9 patent families with 8 granted patents (5 in the U.S.) and additional pending applications. Furthermore, the company recently announced a non-binding term sheet with Neurothera Labs in November 2025 regarding a novel neuroplastogen treatment.

SciSparc Ltd. (SPRC) - Canvas Business Model: Cost Structure

You're looking at the cost side of SciSparc Ltd.'s operations as of late 2025, and honestly, the numbers show a company heavily invested in its pipeline, which is typical for a clinical-stage biotech, but it's burning cash fast. The primary cost drivers are clearly centered around advancing its drug candidates through trials and maintaining the corporate structure needed to manage that science.

The most immediate financial pressure point is the bottom line. SciSparc Ltd. reported a net loss of $9.33 million for the first half of 2025. This loss is substantially higher than the $3.44 million net loss reported for the same period last year, signaling an increase in the cost base relative to revenue, which itself dropped to $0.461 million for H1 2025. That's a major gap to bridge.

The structure of these expenses points directly to the required clinical focus. You see high research and development (R&D) expenses for clinical trials dominating the operational spend. This R&D is the engine, but it's expensive to run, especially when dealing with central nervous system disorder therapies leveraging cannabinoid pharmaceuticals.

Also significant are the general and administrative (G&A) costs for corporate overhead. These cover everything from legal compliance for being listed on Nasdaq to the basic running of the headquarters. When you look at the trailing twelve months (TTM) data available near the end of 2025, the operating expenses are substantial, which is where both R&D and G&A reside.

Here's a quick look at the major operating cost components based on the latest available TTM figures, which give you a clearer picture of the ongoing burn rate:

Cost Component (TTM)	Amount (Millions USD)
Research & Development Expenses	$1.9
Selling, General & Admin Expenses	$6.04
Total Operating Expenses	$7.94

The costs associated with M&A activities and corporate restructuring are also a factor, though perhaps less consistent than R&D. You saw SciSparc Ltd. announce the mutual termination of its Merger Agreement with AutoMax Motors effective October 6, 2025. While the termination itself might involve certain wind-down costs, the prior agreement involved loan structures, such as a $2.0 million loan repayment schedule starting November 20, 2025, with 8% per annum interest, plus an upfront accrued interest payment of $114,523.

Finally, the fixed element of the cost structure involves the human capital required to execute the strategy. The salaries and fees for the specialized scientific and management team are a non-negotiable cost. These experts in cannabinoid pharmaceuticals and CNS disorders command high fees, which are bundled into the G&A and R&D lines. For instance, in a recent period, the company reported having an employee count of 2, with Profits Per Employee at -$3.24M, underscoring the high cost relative to current revenue generation.

You should focus your near-term review on the burn rate implied by these figures. If onboarding takes 14+ days, churn risk rises, but for SciSparc Ltd., the immediate risk is the cash depletion rate given the $9.33 million loss in just six months. Finance: draft 13-week cash view by Friday.

SciSparc Ltd. (SPRC) - Canvas Business Model: Revenue Streams

You're looking at how SciSparc Ltd. is bringing in cash right now, which is a mix of legacy operations, asset monetization, and future potential from recent deals. Honestly, the current picture shows minimal product sales, which is typical for a company focused on clinical-stage drug development. For the first half of 2025, SciSparc Ltd. reported product sales of $0.461 million.

A significant, one-time cash infusion came from divesting a non-core asset. SciSparc Ltd. closed the sale of its majority-owned subsidiary, MitoCareX Bio Ltd., to N2OFF, Inc. on October 20, 2025. From this, SciSparc Ltd. received $700,000 in cash for the sale of 6,622 MitoCareX shares. This transaction immediately boosted liquidity, though it means SciSparc Ltd. no longer holds majority control over MitoCareX.

The resolution of the planned merger with AutoMax Motors Ltd. on October 6, 2025, established clear, near-term, and long-term debt repayment streams that are now central to SciSparc Ltd.'s non-product revenue. This is a crucial shift in cash flow visibility.

Here's a quick look at the concrete financial components driving the current and near-term revenue picture for SciSparc Ltd.:

Revenue Component	Amount/Term	Date/Frequency	Source Reference
H1 2025 Product Sales	$0.461 million	Period ending June 30, 2025	As specified
MitoCareX Asset Sale (Cash)	$700,000	October 20, 2025 (One-time)
AutoMax Loan Repayment (Initial Interest)	$114,523	Upfront payment (Nov 20, 2025)
AutoMax Loan Repayment (Installment Principal)	$60,000 per month	Starting November 20, 2025
AutoMax Loan Repayment (Final Principal)	$4.25 million	January 1, 2028 (Lump Sum)

Looking further out, the intellectual property (IP) strategy is designed to generate future, potentially high-margin revenue, primarily through licensing and milestone payments. SciSparc Ltd. is positioning itself to replicate a successful model for its newly acquired MUSE GERD device IP.

The potential for future revenue from licensed IP and spin-offs is substantial, particularly from the N2OFF transaction:

• Sellers (including SciSparc Ltd.) are entitled to 30% of N2OFF's financing proceeds, capped at $1.6 million over five years.
• Potential milestone-based issuances of up to 25% of N2OFF common stock.

The commercialization of the MUSE GERD device represents a major potential revenue stream by entering a growing market. SciSparc Ltd. intends to pursue global commercialization through exclusive regional distribution partnerships, mirroring Xylo Technologies' prior success.

The market opportunity for the MUSE system is quantified by external analysis:

• Global GERD device market value in 2024 was approximately $2.5 billion.
• Projected market value by 2030 is $3.03 billion.
• This represents a Compound Annual Growth Rate (CAGR) of 3.24% from 2025 to 2030.

To be fair, the upfront payment SciSparc Ltd. hopes to replicate was $3 million received by Xylo for Greater China commercialization in 2019. Finance: draft 13-week cash view by Friday.